Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01304485 · ClinicalTrials.gov registry record · Phase 2
PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma
A Phase 2 study, sponsored by Phoenix Molecular Imaging.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,000
- Enrollment target
NCT01304485 is a Phase 2 study that has completed, run by Phoenix Molecular Imaging. The registered enrollment target is 2,000 participants.
The verdict
NCT01304485, a Phase 2 study, has completed, sponsored by Phoenix Molecular Imaging.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
Positron emission tomography (PET) imaging evaluation in men with recurrent prostate cancer to select patients who may benefit from directed therapy
Interventions
- DRUG Sodium Acetate C11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2011-04 |
| Est. Completion | 2019-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01304485
The ClinicalTrials.gov registry entry for NCT01304485 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phoenix Molecular Imaging, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sodium Acetate C11 is the first listed.
NCT01304485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01304485 about?
NCT01304485 is a clinical study titled "PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma". Positron emission tomography (PET) imaging evaluation in men with recurrent prostate cancer to select patients who may benefit from directed therapy
What is the current status of trial NCT01304485?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,000 participants. The study started on 2011-04. Estimated completion is 2019-01.
What interventions are being tested in trial NCT01304485?
The interventions under investigation include: Sodium Acetate C11 (DRUG).
Who is sponsoring clinical trial NCT01304485?
This trial is sponsored by Phoenix Molecular Imaging, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.